HBIO Q3: revenues $20.6M, net loss narrows to $1.2M; Q4 guidance $22.5-$24.5M

HARVARD BIOSCIENCE INC

2025-Q3 EPS reported -$1.22 vs consensus $0.05 ▼ miss (-2492.2%)

Q3 2025 revenues $20.6M (down 6.4% YoY); gross margin 58.4% vs 58.1%.
Net loss ($1.2M) vs ($4.8M) YoY; adjusted EBITDA $2.0M vs $1.3M.
Cash from operations $1.1M positive vs ($0.8M) in Q3 2024.
Company in active discussions to refinance or repay credit agreement in Q4.
Q4 guidance: revenues $22.5M-$24.5M, gross margin 58%-60%; cites increased demand and backlog.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.